Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Athira Pharma, Inc. ATHA NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
49/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$18.00
+166.7%

Athira Pharma, Inc. (ATHA) is a Biotechnology company in the Healthcare sector, currently trading at $6.75. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ATHA = $18 (+166.7% upside).

Net income is $106M (loss), growing at -8.7%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $803,000 against $28M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 1.88 (strong liquidity). Debt-to-assets is 0.9%. Total assets: $92M.

Analyst outlook: 0 / 5 analysts rate ATHA as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 52/100 (Partial), Income ?/100 (Fail).

$18.00
▲ 166.67% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Athira Pharma, Inc., the average price target is $18.00, with a high forecast of $33.00, and a low forecast of $3.00.
Highest Price Target
$33.00
Average Price Target
$18.00
Lowest Price Target
$3.00

ATHA SharesGrow Score Overview

59/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 52/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ATHA

✓
VALUE Pass
100/100
ATHA trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $18, implying +166.7% from the current price $7. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
ATHA: +0%/yr revenue is, -8.7%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet ATHA: Debt-to-Equity (D/E) ratio 0.03 (conservative), Current ratio is 1.88 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
ATHA: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
~
FUTURE Partial
52/100
Analyst outlook: 0 / 5 analysts rate ATHA as buy (0%). Analyst consensus target is $18 (+166.7% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range2.1955-8.36
Volume70.31K
Avg Volume (30D)1.06M
Market Cap$26.62M
Beta (1Y)2.80
Share Statistics
EPS (TTM)-24.70
Shares Outstanding$4.28M
IPO Date2020-09-18
Employees26
CEOMark J. Litton
Financial Highlights & Ratios
Gross Profit$-68.09M
EBITDA$-102.27M
Net Income$-105.61M
Operating Income$-102.27M
Total Cash$88.33M
Total Debt$803K
Net Debt$-68.47M
Total Assets$92.15M
Price / Earnings (P/E)-0.3
Analyst Forecast
1Y Price Target$18.00
Target High$33.00
Target Low$3.00
Upside+166.7%
Rating ConsensusHold
Analysts Covering5
Buy 0% Hold 100% Sell 0%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS04746L2034

Price Chart

Track all markets on TradingView
ATHA
Athira Pharma, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
2.20 52WK RANGE 8.36

People Also View

NUVB
NUVB
Nuvation Bio Inc.
$4.85
+3.19%
 CTMX
CTMX
CytomX Therapeutics, Inc.
$4.54
+3.42%
 ASMB
ASMB
Assembly Biosciences, Inc.
$29.44
+0.68%
 SPRO
SPRO
Spero Therapeutics, Inc.
$2.78
-0.36%
 ACHL
ACHL
Achilles Therapeutics plc
$1.48
+0.68%
 TIL
TIL
Instil Bio, Inc.
$8.44
+1.02%
 NXTC
NXTC
NextCure, Inc.
$12.77
+3.65%
 NLTX
NLTX
Neoleukin Therapeutics, Inc.
$3.49
+1.45%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message